Dyskinesia – Advances in Understanding the Pathophysiology and Treatment Options
a general effect of L-DOPA treatment. This article will provide a summary of the most important findings from these experimental models and their impact on the search for novel therapeutic options for LID.
Maladaptive Plasticity in L-DOPA-induced Dyskinesia Pre-synaptic Plasticity
Generally, therapeutic doses of L-DOPA given to rodent or primate models of PD typically require a substantial dopaminergic depletion before LID can be established. Even so, some animals with extensive dopamine denervation remain non-dyskinetic after chronic L-DOPA treatment. Therefore, the extent of LID cannot be solely predicted by the degree or pattern of dopaminergic depletion.17 Dopaminergic depletion is a significant risk factor but additional, thus far undetermined factors, must also be key to the development of LID.
Large and rapid fluctuations in extracellular levels of dopamine have been regarded as the prime trigger of the motor complications associated with L-DOPA therapy.18
Accordingly, recent positron
emission tomography studies in PD patients have demonstrated large increases in putaminal dopamine release after L-DOPA administration, which correlate positively with the severity of dyskinesia.19,20
In line with the clinical findings, high striatal levels of dopamine have been reported in L-DOPA-treated dyskinetic rats.21–23
The
fluctuations were originally thought to be due to the loss of dopamine neurons. However, more recently it has been suggested that a reduced expression/dysfunction of the dopamine transporter in the remaining nigrostriatal terminals21,24 serotonergic fibres25 dopamine levels.
and a higher density of striatal may be critical contributors to changes in
As the number of dopaminergic neurons decreases, the ability of the remaining terminals to convert L-DOPA into dopamine is reduced. Eventually, serotonergic neurons become the main site of L-DOPA decarboxylation in the brain. The lack of both dopamine autoreceptors and high-affinity reuptake capacity for dopamine, however, provides a source of unregulated dopamine efflux following exogenous L-DOPA administration.17
A causal link between the serotonin system and LID has recently been demonstrated in which LID was abolished by lesions of ascending 5-HT projections and greatly reduced by agonists of the serotonin autoreceptors 5-HT1A and 5-HT1B.26
Clinical trials with the 5-HT1A agonist sarizotan have demonstrated some improvements in dyskinesia, although the dopamine antagonist activity of this drug may have influenced the overall unimpressive clinical outcome.27,28
blunt the surge of striatal extracellular dopamine following L-DOPA administration.22
Pardoprunox (SLV308) is
also being evaluated as a 5HT1A agonist with additional dopamine D2/3-receptor partial agonist activity. It has already shown some success as a de novo treatment in early PD.29
As these pulsatile events are closely correlated with LID, current pharmaceutical strategy has moved towards the concept of continuous dopaminergic stimulation (CDS). CDS aims to prolong
Dysregulated dopamine release may contribute substantially to the pulsatile levels of dopamine caused by intermittent L-DOPA administration.18
EUROPEAN NEUROLOGICAL REVIEW
The delivery of CDS moved forward significantly with the introduction of devices such as the duodenal L-DOPA pump (DuoDopa) and dopamine receptor-agonist patches. New gene therapy approaches should also assist in this endeavour, utilising viral vector-mediated delivery of coding sequences for essential enzymes in the synthesis of dopamine.33
The enzymes involved are tyrosine
hydroxylase, the rate-limiting enzyme in dopamine synthesis, L-amino acid decarboxylase, which converts L-DOPA into dopamine, and guanosine 5’-triphosphate cyclohydrolase 1, which synthesises
35
Abnormal firing patterns in GPi/SNr
DBS
GABA dyn
D1 rec
Fluctuating dopamine (DA) (filled blue circles) levels after peripheral L-DOPA administration are considered the prime trigger of L-DOPA-induced dyskinesia (LID). Both unregulated DA release from serotonergic neurons and increased blood–brain barrier permeability may further exacerbate these fluctuating levels of DA. The expression of LID is also associated with an overactive signalling in cortical motor areas as well as supersensitised D1 dopamine receptors (D1 rec), causing abnormal signalling in striatal medium spiny neurons (MSNs) and long-term alternations in gene and protein expression. Overactive γ-Aminobutyric acid (GABA)ergic projections from striatum to the output nuclei of the basal ganglia leads to a large amount of GABA (green circles) being released in the output structures following L- DOPA administration. This neurochemical imbalance gives rise to abnormal firing patterns in GPi/SNr, which most likely represent the neural code for dyskinesia. DBS = deep brain stimulation; GPi = globus pallidus interna; SNr = substantia nigra pars reticulata.
These drugs were later found to
but two meta-analyses suggest that the consequence is significantly worse dyskinesia.31,32
the effects of L-DOPA, with the dual benefit of increases in ‘on-time’ and (hopefully) a reduction in dyskinesia. This approach is reportedly successful with the use of slow-release formulations of L-DOPA and adjuvant catechol-o-methyltransferase inhibitors improving ‘on’ time30
Figure 1: Pathophysiological Findings in L-DOPA-induced Dyskinesia and New Pharmacological Targets and Strategies Under Investigation
Cortex Overactive signalling
Striatum Glutamate
Large intermittent surges of extracellular DA
Angiostatic treatment 5-HT autoreceptor agonists Continuous dopamine stimulation
Abnormal signaling in striatal MSNs
Glutamatergic antagonists Non-dopaminergic agonists/ antagonists. Inhibitors of specific intracellular pathways
Gene transcription changes
AMPA rec NMDA rec mGluR5 5-HT axon
Dopamine D1 rec DA axon
capillary
GPi/SNr Capillary
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108